Journal Article DKFZ-2025-00346

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Individualized patient tumor organoids faithfully preserve human brain tumor ecosystems and predict patient response to therapy.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2025
Elsevier Amsterdam [u.a.]

Cell stem cell 32(4), 652-669.e11 () [10.1016/j.stem.2025.01.002]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: Tumor organoids are important tools for cancer research, but current models have drawbacks that limit their applications for predicting response to therapy. Here, we developed a fast, efficient, and complex culture system (IPTO, individualized patient tumor organoid) that accurately recapitulates the cellular and molecular pathology of human brain tumors. Patient-derived tumor explants were cultured in induced pluripotent stem cell (iPSC)-derived cerebral organoids, thus enabling culture of a wide range of human tumors in the central nervous system (CNS), including adult, pediatric, and metastatic brain cancers. Histopathological, genomic, epigenomic, and single-cell RNA sequencing (scRNA-seq) analyses demonstrated that the IPTO model recapitulates cellular heterogeneity and molecular features of original tumors. Crucially, we showed that the IPTO model predicts patient-specific drug responses, including resistance mechanisms, in a prospective patient cohort. Collectively, the IPTO model represents a major breakthrough in preclinical modeling of human cancers, which provides a path toward personalized cancer therapy.

Keyword(s): brain metastasis ; glioblastoma ; patient tumor organoid ; predictive patient model ; temozolomide ; tumor heterogeneity

Classification:

Note: DKFZ-ZMBH Alliance / #EA:A240# / HI-TRON / 2025 Apr 3;32(4):652-669.e11

Contributing Institute(s):
  1. A240 Molekulare Neurogenetik (A240)
  2. KKE Neuropathologie (B300)
  3. DKTK HD zentral (HD01)
  4. KKE Neuroimmunologie und Hirntumorimmunologie (D170)
  5. KKE Neuroonkologie (B320)
  6. Personalisierte Medizinische Onkologie (A420)
Research Program(s):
  1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2025
Database coverage:
Medline ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Essential Science Indicators ; IF >= 20 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > D170
Public records
Publications database

 Record created 2025-02-13, last modified 2025-04-07



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)